Free Trial
NASDAQ:RNAC

Cartesian Therapeutics (RNAC) Stock Price, News & Analysis

Cartesian Therapeutics logo
$10.50 -0.07 (-0.66%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$10.50 0.00 (0.00%)
As of 04/17/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cartesian Therapeutics Stock (NASDAQ:RNAC)

Key Stats

Today's Range
$10.19
$10.67
50-Day Range
$9.52
$19.67
52-Week Range
$8.85
$41.87
Volume
96,202 shs
Average Volume
117,185 shs
Market Capitalization
$272.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.14
Consensus Rating
Moderate Buy

Company Overview

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Cartesian Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

RNAC MarketRank™: 

Cartesian Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 639th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cartesian Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cartesian Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cartesian Therapeutics are expected to decrease in the coming year, from $4.56 to ($3.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cartesian Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cartesian Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Cartesian Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    24.65% of the float of Cartesian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cartesian Therapeutics has a short interest ratio ("days to cover") of 22.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cartesian Therapeutics has recently increased by 3.45%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Cartesian Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cartesian Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.65% of the float of Cartesian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cartesian Therapeutics has a short interest ratio ("days to cover") of 22.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cartesian Therapeutics has recently increased by 3.45%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Cartesian Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
  • Search Interest

    3 people have searched for RNAC on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Cartesian Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    57.90% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cartesian Therapeutics' insider trading history.
Receive RNAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RNAC Stock News Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Headlines

RNAC Stock Analysis - Frequently Asked Questions

Cartesian Therapeutics' stock was trading at $17.91 at the beginning of 2025. Since then, RNAC shares have decreased by 41.4% and is now trading at $10.50.
View the best growth stocks for 2025 here
.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) released its quarterly earnings results on Thursday, August, 8th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.81) by $1.35. The company earned $33.45 million during the quarter, compared to the consensus estimate of $6 million.

Cartesian Therapeutics shares reverse split before market open on Friday, April 5th 2024. The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Top institutional investors of Cartesian Therapeutics include Rhumbline Advisers (0.05%). Insiders that own company stock include Blaine Davis, Metin Kurtoglu and Milos Miljkovic.
View institutional ownership trends
.

Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/08/2024
Today
4/19/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RNAC
Previous Symbol
NASDAQ:RNAC
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$42.14
High Stock Price Target
$50.00
Low Stock Price Target
$39.00
Potential Upside/Downside
+301.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
2.30
P/E Growth
N/A
Net Income
$-219,710,000.00
Net Margins
-510.72%
Pretax Margin
-550.35%

Debt

Sales & Book Value

Annual Sales
$38.91 million
Price / Cash Flow
N/A
Book Value
($82.38) per share
Price / Book
-0.13

Miscellaneous

Free Float
10,700,000
Market Cap
$272.02 million
Optionable
Optionable
Beta
0.55
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:RNAC) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners